July 4, 2016
GlycoBiomarker Leading Innovation Co. Ltd.
GL-i and Sysmex pursuing joint development to provide new diagnostic reagents employing glycosylation markers
GlycoBiomarker Leading Innovation Co. Ltd. (“GL-i”, HQ and research laboratory: Tsukuba, Ibaraki Prefecture; President and CEO: Kazuyuki Takeo) and Sysmex Corporation (HQ: Kobe, Hyogo Prefecture, Japan; Chairman and CEO: Hisashi Ietsugu) pursue the joint development of new diagnostic reagents detecting glycoprotein biomarkers.
Glycans are present on cell surfaces and in the blood and often referred to as accessories for proteins. As the state of the cells, such as normal or abnormal, changes, the constituents of the glycans decorating the cells change drastically. Rather than the conventional approach, e.g., measuring changes in the amounts of proteins (antigens and antibodies), detection of “qualitative changes in the proteins” based on a difference in the glycan constituents is expected to provide new clinical value which was unavailable in the past.
In the field of immunochemistry, the National Institute of Advanced Industrial Science and Technology (AIST) and Sysmex have developed a relationship through the joint development of a hepatic fibrosis test reagent (HISCL M2BPGi® Assay Kit) using a fibrosis-related glycoprotein isomer for the first time in the world.
GL-i was established as an independent entity by AIST in the expectation of enhancing the value of its intellectual property and expanding it worldwide. Approved as an “AIST start-up”, the technology transfer venture company of AIST, GL-i is promoting practical application of research outcomes related to glycoprotein analysis or glycoproteomics technology (clinical reagents, drug discovery) developed by AIST.
AIST, GL-i, and Sysmex are working together to jointly develop new biomarkers for bile duct cancer and other diseases toward practical realization. In this collaborative alliance, AIST conducts marker discovery and other basic research, GL-i handles clinical research, and Sysmex develops diagnostic reagents and obtains regulatory approval, as well as manufactures and commercializes the outcomes.
We, GL-i, develop novel clinical diagnostic technologies based on the “glycoprotein analysis platforms”, and further, pursue the drug discovery not limited in diagnostic agents but also medicinal drugs applying the glycoproteomics technologies. GL-i aims to lead glycan-related medical applications in both diagnostics and clinical medicines.
|Established:||March 3, 2015|
|Head Office Location:||1-1-1 Umezono, Tsukuba, Ibaraki 305-8560 Japan (within the AIST Tsukuba Central)|
|President, CEO:||Kazuyuki Takeo|
|Director, CTO:||Atsushi Kuno, concurrently Chief senior researcher, Biotechnology Research Institute for Drug Discovery, AIST|
|Director, CFO:||Masayuki Ushida|
December 26, 2013, Press release:
Sysmex succeeds in world's first practical application of technology employing a glycosylation marker to test hepatic fibrosis: Technology allows the degree of hepatic fibrosis, from hepatitis to cirrhosis of the liver, to be determined swiftly
January 5, 2015, Press release:
Hepatic fibrosis test reagent (HISCL M2BPGi Assay Kit) receives approval for health insurance coverage—Speedy Blood sample-based test for measuring the progression of hepatic fibrosis from chronic hepatitis to cirrhosis of the liver
GlycoBiomarker Leading Innovation Co. Ltd. (GL-i)
1-1-1 Umezono, Tsukuba, Ibaraki 305-8568 Japan
E-mail: firstname.lastname@example.org / URL:http://www.gl-i.co.jp/en/index_e.html